Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 05, 2026 | June 15, 2026 |
| Arcturus Therapeutics Ltd.ARCT · Entity 160417 | Director | January 01, 2019 | January 02, 2019 |
| Evolus, Inc.EOLS · Entity 5341 | Director | January 27, 2023 | February 01, 2023 |
| RESMED INCRMD · Entity 2692 | Director | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date June 05, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-06-05 | Direct | 15,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Arcturus Therapeutics Ltd.
Report date January 01, 2019 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 86,452 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 86,452 F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F2: Vesting monthly over a two year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F3: Vesting monthly over a one year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
F2: Vesting monthly over a two year period from August 24, 2018.
F3: Vesting monthly over a one year period from August 24, 2018.
Evolus, Inc.
Report date January 27, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,174 |
Reported balance
After 2023-01-27 transaction · row 1
1 source rowRow 1 · 2023-01-27 · Grant · Acquired 8,293 · Balance 43,174 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.25 · Expires 2033-01-27 | Direct | 11,789 |
Reported balance
After 2023-01-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-27 · Grant · Acquired 11,789 · Balance 11,789 F2: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 10,000 |
Reported balance
Holding disclosure · report date 2023-01-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer
F2: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
RESMED INC
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 51,803 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 970 · Balance 51,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date May 03, 2018 · Filed May 07, 2018
Section 16 reporting ended · disclosed 2018-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 36,713 |
Last balance in matching sequence
After 2018-05-03 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2018-05-03 · Exercise / conversion · Acquired 16,844 · Balance 35,490 F1: On May 3, 2018, the Reporting Person retired from his position as a member of the Issuer's Board of Directors. Pursuant to deferral elections made by the Reporting Person, all shares underlying Restricted Stock Units ("RSUs") subject to such deferrals were delivered to the Reporting Person promptly following the Issuer's 2018 Annual Meeting of Stockholders on May 3, 2018, the date on which the Reporting Person retired. F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 2 · 2018-05-03 · Exercise / conversion · Acquired 6,000 · Balance 41,490 F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 3 · 2018-05-03 · Tax withholding · Disposed 4,777 · Balance 36,713 F3: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise. F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-03 · Exercise / conversion · Disposed 2,833 · Balance 0 F4: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-03 · Exercise / conversion · Disposed 2,833 · Balance 0 F5: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-03 · Exercise / conversion · Disposed 3,725 · Balance 0 F6: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-03 · Exercise / conversion · Disposed 2,501 · Balance 0 F7: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-03 · Exercise / conversion · Disposed 2,822 · Balance 0 F8: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-03 · Exercise / conversion · Disposed 2,130 · Balance 0 F9: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.45 · Expires 2018-05-22 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-03 · Exercise / conversion · Disposed 6,000 · Balance 0 F10: The option, representing a right to purchase a total of 6,000 shares, was granted on May 22, 2008 and is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 3, 2018, the Reporting Person retired from his position as a member of the Issuer's Board of Directors. Pursuant to deferral elections made by the Reporting Person, all shares underlying Restricted Stock Units ("RSUs") subject to such deferrals were delivered to the Reporting Person promptly following the Issuer's 2018 Annual Meeting of Stockholders on May 3, 2018, the date on which the Reporting Person retired.
F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards.
F3: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise.
F4: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested.
F5: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested.
F6: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested.
F7: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested.
F8: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested.
F9: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested.
F10: The option, representing a right to purchase a total of 6,000 shares, was granted on May 22, 2008 and is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2016 Filed Nov 2, 2016 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 2,541 | $59.73 | $151,773.93 |
DisclosureSEC source: 0001209191-16-148016 · doc4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 18,646 F2 · shares: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 6,000 | $25.30 | $151,800.00 |
DisclosureSEC source: 0001209191-16-148016 · doc4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 21,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 2,967 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · derivative · entry 7 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 2,967 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 948 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · derivative · entry 6 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,085 Underlying: ResMed Common Stock · 948 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 16,085 | $0.00 Strike: $25.54 | $0.00 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · derivative · entry 5 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 16,085 shares Expires 2016-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $64.70 | $1,293,960.00 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · nonDerivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,978 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 64.32 to 65.20. The price reported above represents the weighted average sales price. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 948 | $33.70 | $31,947.60 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 2,967 | $33.70 | $99,987.90 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 16,085 | $25.54 | $410,810.90 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:44 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $25.54 | $0.00 |
DisclosureSEC source: 0001140361-16-079166 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2016-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:44 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $67.29 | $1,345,760.00 |
DisclosureSEC source: 0001140361-16-079166 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,978 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 66.97 to 67.43. The price reported above represents the weighted average sales price. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:44 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $25.54 | $510,800.00 |
DisclosureSEC source: 0001140361-16-079166 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.